{"result": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing clinical information and guidelines, including management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>ALENDRONATE<|>EVENT<|>Alendronate is a medication used to treat osteoporosis, particularly in postmenopausal women, and its effects on bone mass are discussed.)\n##\n(\"entity\"<|>DENOSUMAB<|>EVENT<|>Denosumab is a fully human monoclonal antibody against RANKL, used to treat osteoporosis by inhibiting osteoclast formation and reducing bone resorption.)\n##\n(\"entity\"<|>IBANDRONATE<|>EVENT<|>Ibandronate is a medication for osteoporosis that has been compared to alendronate regarding its effectiveness on non-vertebral fractures.)\n##\n(\"entity\"<|>RALOXIFENE<|>EVENT<|>Raloxifene is a selective estrogen receptor modulator that reduces the risk of breast cancer and affects bone metabolism.)\n##\n(\"entity\"<|>OSTEOPOROSIS<|>EVENT<|>Osteoporosis is a condition characterized by weakened bones, leading to an increased risk of fractures, particularly in postmenopausal women.)\n##\n(\"entity\"<|>GLUCOCORTICOIDS<|>EVENT<|>Glucocorticoids are a class of steroid hormones that can affect bone health and are associated with osteonecrosis.)\n##\n(\"relationship\"<|>ALENDRONATE<|>OSTEOPOROSIS<|>Alendronate is used as a treatment for osteoporosis, particularly in postmenopausal women<|>8)\n##\n(\"relationship\"<|>DENOSUMAB<|>OSTEOPOROSIS<|>Denosumab is used to treat osteoporosis by inhibiting osteoclast formation<|>8)\n##\n(\"relationship\"<|>IBANDRONATE<|>OSTEOPOROSIS<|>Ibandronate is a treatment option for osteoporosis, compared to alendronate<|>7)\n##\n(\"relationship\"<|>RALOXIFENE<|>OSTEOPOROSIS<|>Raloxifene is used to treat osteoporosis and has effects on breast cancer risk<|>6)\n##\n(\"relationship\"<|>GLUCOCORTICOIDS<|>OSTEOPOROSIS<|>Glucocorticoids can negatively impact bone health and contribute to osteoporosis<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de 2019).\n                                                                                                             • Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Rosen CJ, Schmader KE, eds.\n         B. El alendronato no tiene indicación para utilizarse en la osteoporosis del varón.                   UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n         C. El efecto beneficioso del alendronato sobre la masa ósea desaparece a los 3 meses\n             de suspender el tratamiento.                                                                    En mujeres posmenopáusicas con osteoporosis: (señale la opción cierta)\n         D.  El ibandronato tiene un peor resultado sobre las fracturas no vertebrales que               21\n             el alendronato.                                                                                 A. El raloxifeno reduce el riesgo de fracturas vertebrales y de cadera.\n                                                                                                             B. El tratamiento con denosumab reduce\n         COMENTARIO                                                                                              los marcadores de resorción ósea.\n         Los tratamientos antirresortivos inhiben la resorción ósea mediante supresión de la acti-           C. La calcitonina ha demostrado reducción\n         vidad osteoclástica. Ralentizar el ciclo de remodelación permite que la formación ósea se               de fracturas de cadera.\n         equilibre con la resorción, aumentando de este modo la mineralización de la matriz estabili-        D.  El ranelato de estroncio reduce eventos cardiovasculares.\n         zando la microestructura trabecular. Los antirresortivos incrementan la DMO y disminuyen\n         el riesgo de fractura, pero su eficacia varía.                                                      COMENTARIO\n         Los bisfosfonatos son los antirresortivos más utilizados y a menudo se consideran el trata-         El denosumab es          un anticuerpo monoclonal completamente                     humano     contra    el RANKL,\n         miento de elección de la osteoporosis posmenopáusica grave y también en la osteoporosis             el principal factor diferenciador del osteoclasto. Este anticuerpo inhibe la formación de\n         del varón. El alendronato y el risedronato son dos bisfosfonatos nitrogenados de segunda            osteoclastos, disminuye la resorción ósea, aumenta la DMO y baja el riesgo de fractura.\n         generación, son efectivos para reducir la resorción ósea y aumentar la DMO. En mujeres\n         posmenopáusicas con osteoporosis confirmada, el alendronato y el risedronato disminu-               A diferencia de los bisfosfonatos, el denosumab no permanece en el esqueleto y por eso es\n         yeron casi un 50% las fracturas vertebrales, de cadera y no vertebrales, especialmente              necesario administrarlo cada 6 meses para mantener su eficacia. De hecho, la interrupción\n         durante el primer año de tratamiento.                                                               del denosumab puede causar un aumento de rebote de la resorción ósea.\n         Igual que con otros antirresortivos, el aumento de la DMO es responsable de una pequeña             Uno de los estudios clínicos con 60 mg de denosumab cada 6 meses demostró que des-\n         proporción      de  su  eficacia antifractura. Por tanto, las evaluaciones de la DMO de segui-      pués    de 3   años el    denosumab        mejoró    la  DMO    en la columna vertebral y en la cadera\n         miento pueden subestimar considerablemente la disminución del riesgo de fractura.                   comparado con el placebo. Además, los marcadores bioquímicos de recambio óseo dis-\n                                                                                                             minuyeron significativamente.\n         Estudios clínicos recientes han mostrado que estos fármacos pueden administrarse de ma-\n         nera segura durante 5 años como mínimo sin efecto adverso en la fortaleza ósea. Es más,             Los moduladores selectivos del receptor de estrógeno, como el tamoxifeno y el                                 raloxi-\n                                                                                                             feno bloquean las acciones del estrógeno en la mama, pero actúan como agonistas de\n\n\n\n390                                                                                                                                                                                                                                   391\n---\n                                                                                                                                                                   METABOLISMO FOSFOCÁLCICO,                                             TUMORES                           7\n                                                                                                                                                                                                  NEUROENDOCRINOS Y MEN\n\n\n\n         estrógeno en el hueso. Ambos fármacos se han asociado a una reducción de cáncer de                                                     mento en las tasas de apoptosis de los osteoblastos y osteocitos maduros. Esta apoptosis\n         mama. La concentración de colesterol en lipoproteínas de densidad baja disminuye tam-                                                  también puede explicar la tendencia de los glucocorticoides a causar osteonecrosis.\n         bién en pacientes que reciben este tratamiento.                                                                                        Además, los glucocorticoides alteran la dinámica secretora de la PTH (reducen la secreción\n         El raloxifeno aumenta liger\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}